Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H13NO |
| Molecular Weight | 151.2056 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)CC1=CC=CC(O)=C1
InChI
InChIKey=WTDGMHYYGNJEKQ-ZETCQYMHSA-N
InChI=1S/C9H13NO/c1-7(10)5-8-3-2-4-9(11)6-8/h2-4,6-7,11H,5,10H2,1H3/t7-/m0/s1
| Molecular Formula | C9H13NO |
| Molecular Weight | 151.2056 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Gepefrine (Pressionorm and Wintonin) is an antihypotensive agent. It was used for therapy of orthostatic dysregulation. One hour after oral administration of 30 mg or 45 mg gepefrine the blood pressure increased significantly at rest and more markedly on standing and during the step test. Gepefrine led to a reduction in pathological orthostatic regulation during the early phase as well as to the prevention of subjective and objective signs of orthostatic adjustment disorder during the late phase. Patients with insufficient rise in blood pressure during the step test (80 watts) showed after gepefrine a distinct tendency towards normalisation and the regression of subjective states of exhaustion. Gepefrine caused on average no substantive alternations in heart rate during all phases of the investigation. Complications or side-effects due to the method or the medicament were not observed.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0014061 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13923440 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4002776
Curator's Comment: The action of the pressor agent gepefrine (D form of 3-hydroxyphenyl-2-aminopropan) was evaluated in 16 patients with typical clinical symptoms of orthostatic adjustment disorders
One hour after oral administration of 30 mg or 45 mg gepefrine the blood pressure increased significantly at rest and more markedly on standing and during the step test.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:18:58 GMT 2025
by
admin
on
Mon Mar 31 18:18:58 GMT 2025
|
| Record UNII |
V51RRX51VH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
C01CA15
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
||
|
WHO-VATC |
QC01CA15
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60172191
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | |||
|
V51RRX51VH
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | |||
|
100000084541
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | |||
|
C72920
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | |||
|
SUB07896MIG
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | |||
|
41157
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | RxNorm | ||
|
C045355
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | |||
|
DB13703
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | |||
|
1290
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | |||
|
219105
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | |||
|
4270
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | |||
|
m1177
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL2105064
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY | |||
|
18840-47-6
Created by
admin on Mon Mar 31 18:18:58 GMT 2025 , Edited by admin on Mon Mar 31 18:18:58 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |